Summer Sale
50% off Premium Yearly
00days
00hrs
00mins
00secs
NASDAQ:AMGN
Amgen Inc. (AMGN)
336.13
-1.47 (0.44%)
as of Jun 18, 2026, 10:19:00 pm Market Open.
47 watching
Financials 
Technical Analysis 0
TOP PICK
Are big worries about inflation and the economy and war. So, be in the US dollar, which should rally if the world goes deflationary. This is also a big name, and there's a massive rotation into the drug companies. He target $272. It pays a 3% dividend. (Analysts’ price target is $242.24)
Brian Acker, CAOwned
biotechnologypharmaceutical
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium contentPAST TOP PICK
TOP PICK
This name has been beaten up and now offers value. There is concern that markets could experience a pull-back and one way to play that is this one. It is a large entity in the healthcare space and has under-performed its space. As we push out of the pandemic we are going to see increased regular appointments and more diagnostics. This company offers decent value. (Analysts’ price target is $243.05)
Andrew PyleOwned
biotechnologypharmaceutical
Premium contentTOP PICK
Stockchase Research Editor: Michael O'Reilly AMGN just released earnings and the 12% increase in revenues and 5% increase in EPS were likely held back due to government mandates to focus health spending towards COVID-19 projects. The company is now benefitting from the release of new arthritis and metastatic colorectal cancer treatments. They also signed a deal to partner with Eli Lilly to manufacture a coronavirus antibody treatment, when it is ready. They pay a good dividend, backed by a 50% payout ratio. We would trade this with a stop-loss of $205 and a target of of $255 -- over 15% upside. Yield 2.91% (Analysts’ price target is $254.12)
biotechnologypharmaceutical
WATCH
A pure biotech company with a strong biosimilar business with a great core franchise in immunology. Their oncology business is also robust. They had a recent miss in one of their trials, which was the second miss this year. (There is another phase 3 trial this year.) He wants to see either more execution on their R&D drugs or backfill through some M&A in coming years. He's closely watching this.
biotechnologypharmaceutical
HOLD
The biotech grandddaddy. A great company that's produced some fine drugs, but other technologies have taken the shine off this stock. New drugs haven't driven the stock up. It does trade at a reasonable 11x earnings. A decent stock and it's stable, but lacks the punch of its peers. It depends what happens in the US election in Nov. 2020 too.
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick Jul 05/18, Up 3%) One of the world's largest biotech companies. They have 3-4 blockbuster drugs in the pipeline in phase 1 & 2. It's an under-owned stock. Enbrel, their largest-selling drug, is undergoing a parent review. If Amgen wins--which he thinks will happen--then there'll be a 12% stock boost; if not, it will fall 12%. Either way, after this review, Amgen is still worth buying.
Paul MacDonaldOwned
biotechnologypharmaceutical
TOP PICK
Large cap diversified biotech company. Seeing shorts because of a patent dispute. Diversified pipeline of drugs. Valuation is attractive. Buy this as a basket. Yield is 3.27%. (Analysts’ price target is $206.95)
Paul MacDonaldOwned
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick Jul 05/18, Up 10%) He held onto this over the summer, despite expecting autumnal volatility. It's a diversified biotech and big in bio-similars, so AMGN would benefit from an uptick here. It's reasonably priced.
Paul MacDonaldOwned
biotechnologypharmaceutical
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
